A detailed history of California State Teachers Retirement System transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, California State Teachers Retirement System holds 10,705 shares of LCTX stock, worth $7,386. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,705
Previous 10,705 -0.0%
Holding current value
$7,386
Previous $10,000 10.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.89 - $1.47 $2,346 - $3,874
-2,636 Reduced 19.76%
10,705 $10,000
Q1 2024

May 15, 2024

SELL
$0.86 - $1.48 $7,310 - $12,581
-8,501 Reduced 38.92%
13,341 $19,000
Q4 2023

Feb 13, 2024

SELL
$0.91 - $1.35 $6,036 - $8,954
-6,633 Reduced 23.29%
21,842 $23,000
Q3 2023

Nov 14, 2023

SELL
$1.16 - $1.53 $16,765 - $22,113
-14,453 Reduced 33.67%
28,475 $33,000
Q2 2023

Aug 21, 2023

BUY
$1.26 - $1.53 $54,089 - $65,679
42,928 New
42,928 $60,000
Q2 2022

Aug 15, 2022

SELL
$1.12 - $1.61 $60,094 - $86,386
-53,656 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$1.21 - $2.48 $17,090 - $35,027
-14,124 Reduced 20.84%
53,656 $83,000
Q4 2021

Feb 15, 2022

BUY
$1.84 - $2.68 $4,741 - $6,906
2,577 Added 3.95%
67,780 $166,000
Q3 2021

Nov 15, 2021

SELL
$2.26 - $2.86 $230,956 - $292,271
-102,193 Reduced 61.05%
65,203 $164,000
Q2 2021

Aug 16, 2021

BUY
$2.17 - $3.0 $363,249 - $502,188
167,396 New
167,396 $477,000
Q2 2020

Aug 17, 2020

SELL
$0.71 - $1.18 $119,587 - $198,750
-168,433 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$0.6 - $1.58 $1,155 - $3,041
1,925 Added 1.16%
168,433 $139,000
Q3 2019

Nov 15, 2019

BUY
$0.85 - $1.24 $141,531 - $206,469
166,508 New
166,508 $163,000

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $117M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track California State Teachers Retirement System Portfolio

Follow California State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.